Ahead of disease

Innovation is at the heart of achieving our purpose: to unite science, technology and talent to get ahead of disease together.

How our research and development (R&D) approach helps us get Ahead Together

In Belgium we have a rather impressive ecosystem, particularly due to the quality of our universities. The many clinical developments are made possible by collaboration between private and public partners, the very active biopharmaceutical fabric and structure, and the biotech clusters in the north and south of the country of which we can be very proud. Designing the vaccines and medicines that will meet the needs of tomorrow is what drives the passion of the research and development teams on a daily basis.
Jamila Louahed Head of R&D and Rixensart site

Jamila Louahed

Head of R&D Rixensart

Key facts about R&D at GSK in Belgium:

  • researchers working in research and development for vaccines.

  • vaccines currently in development.

  • euros investment in R&D in 2023.

    1.5 billion
Une scientifique dépose des fioles dans une machine dans un laboratoire


We’re combining the power of genetic and genomic insights into what causes disease, with the speed and scale of artificial intelligence and machine learning (AI/ML) to make better predictions about who a treatment might work for, and why.

We believe this powerful combination of data and technology holds the key to fundamentally transforming medical discovery for the better, improving R&D success rates and shaping how even the most challenging diseases, like neurological conditions and cancer, can be both prevented and treated.

Key facts about R&D at GSK Global:

  • vaccines and medecines in our pipeline.

  • euros invested in R&D in 2023.

    7.3 billion

Un employé de GSK Wavre sélectionne une fiole

Our pipeline

As a global biopharma leader, we invest heavily in our industry-leading pipeline of new products that help us to get ahead of disease together.

  • 71 potential vaccines and medicines
  • 70% of our pipeline is based on the science of the immune system
  • 18 assets in phase III/registration in 2023

More on our pipeline

Une scientifique concentrée sur son travail sur une machine en laboratoire

Therapeutic areas

The four areas of human health we focus on to get ahead of disease are: infectious diseases, HIV, oncology and immunology.

We remain open to opportunities outside these core areas where the science aligns with our strategic approach.

More on our therapeutic areas

Une scientifique presse un bouton sur un compteur dans un laboratoire

How we apply technology to get Ahead Together

We are at the forefront of health-related advances in science and technology, working to create innovative solutions to a range of healthcare challenges.

Advanced technology platforms are central to our R&D approach. We have expertise in AI and functional genomics. Our dedicated global in-house AI team is using machine learning to unlock the potential of complex genetic data with never-before-seen levels of speed, precision and scale.

More on our technologies

Deux scientifiques travaillant dans un laboratoire

Clinical trials at GSK

Diseases and medicines can affect people differently depending on their race, ethnicity, sex or age. It’s therefore vital that we represent the real-world disease population in our clinical trials to advance our understanding of new vaccines and medicines, to create better health outcomes for the patients who rely on us.

Find out about our clinical trials process, how we work with doctors and volunteers throughout this process, and how to become a research volunteer.   

More on our clinical trials

Our Global R&D locations

Our leading R&D centres in the UK, US, Belgium and Italy are pivotal in helping us to get ahead of disease around the world.

Factory of the Future

GSK is proud to have been awarded the "Factory of the Future" label, which rewards the efforts of employees who help keep GSK at the forefront of innovation and the move towards Industry 4.0 through pioneering digital and technological projects in the sector.